2 Followers on Owler

Altavant Sciences is a biopharmaceutical company that develops and commercializes drug-based therapy for the treatment of respiratory diseases...

Read more

Altavant Sciences is a biopharmaceutical company that develops and commercializes drug-based therapy for the treatment of respiratory diseases...

Read more
Est. Annual Revenue
$100K-5.0M
Agree?
Est. Employees
25-100
Agree?
Acquisitions
1

News

Dec 08, 2022
PMLiVE
Altavant Sciences: Enzyvant and Altavant announce merger to accelerate rare disease therapies
May 06, 2022
FirstWord Pharma
Altavant Sciences: Altavant Sciences Presents Data Showing Potential For Combination Of Rodatristat Ethyl And Ambrisentan In Model Of Pulmonary Arterial Hypertension
May 02, 2022
Markets Insider
Altavant Sciences: ALTAVANT SCIENCES PRESENTED DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530
Apr 25, 2022
Markets Insider
Altavant Sciences: ALTAVANT SCIENCES TO PRESENT DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530
Sep 13, 2021
Markets Insider
Altavant Sciences: Altavant Sciences Highlights Ongoing Phase 2b ELEVATE 2 Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at European Respiratory Society Annual Congress
May 10, 2021
Markets Insider
Altavant Sciences: Altavant Sciences Provides Update on Clinical Plan for PAH Candidate, Rodatristat Ethyl, at Upcoming American Thoracic Society Annual Meeting
May 06, 2021
GlobalNewswire
Press Release: Altavant Sciences : Altavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial Hypertension
Apr 26, 2021
MarketScreener
Altavant Sciences: Cary, N.C. and Basel, Switzerland s Finds Nebulized ALTA-2530 Retains Potency and Reaches Target Lung Tissues, Supporting Continued Investigation for Treatment of BOS
Apr 21, 2021
GlobalNewswire
Press Release: Altavant Sciences : Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting
Feb 18, 2021
MarketScreener
Altavant Sciences: Altavant Sciences Initiates Chemical Lung Injury Program in Collaboration with the BARDA and NIAID

Altavant Sciences Competitors

1
2
3
4
5
6
7
8
9
10
See 13+ competitors

Altavant Sciences News

Altavant Sciences Press Releases

Altavant Sciences Headquarters

6501 Weston Parkway Suite 330

Cary, North Carolina27513

Driving Directions »

Altavant Sciences Summary

ABOUT

Overview

Altavant Sciences is a biopharmaceutical company that develops and commercializes drug-based therapy for the treatment of respiratory diseases. Altavant Sciences was founded in 2018. Altavant Sciences' headquarters is located in Cary, North Carolina, ...

CEO

Altavant Sciences's CEO, Bill Symonds, currently has an approval rating of 90%. Altavant Sciences's primary competitors are Breath Therapeutics, Lung Therapeutics, Aqualung Therapeutics and 10 more.

Funding

Funding data cannot be found related to Altavant Sciences

Investments

Recent investment data cannot be found related to Altavant Sciences

Frequently Asked Questions about Altavant Sciences

  1. When was Altavant Sciences founded?

    Altavant Sciences was founded in 2018
  2. Who is Altavant Sciences's CEO?

    Altavant Sciences's CEO is Bill Symonds
  3. How much revenue does Altavant Sciences generate?

    Altavant Sciences generates $4.5M in revenue
  4. How much funding does Altavant Sciences have?

    Altavant Sciences has historically raised $0 in funding
  1. Where is Altavant Sciences's headquarters?

    Altavant Sciences's headquarters is in Cary North Carolina, USA
  2. How many employees does Altavant Sciences have?

    Altavant Sciences has 25 employees
  3. What sector does Altavant Sciences operate in?

    Altavant Sciences is in Biotechnology, Pharmaceuticals
  4. Who are Altavant Sciences's competitors?

    Altavant Sciences's top competitors are Breath Therapeutics, Lung Therapeutics, Aqualung Therapeutics

Trending Companies